Caligor appoints Andrea Chopek and Craig LaMarca to Clinical Trial Services Business Unit

Monday, February 13, 2017

Caligor Opco, which specializes in global comparator sourcing, early access to medicines and drug life-cycle management, has named two pharmaceutical executives to its Clinical Trial Services (CTS) business unit. Andrea Chopek has been appointed global head of Business Development for CTS. Craig LaMarca has been named global head of Business Development for TrialAssist, a business line under CTS. Both positions are new for the company, which recently expanded its international operations with the opening of a state-of-the-art, 33,000-square-foot facility in the UK.

[Read More]

Clinigen launches Japanese business to strengthen Asian presence

Monday, October 24, 2016

Clinigen, a global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen K.K. further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen K.K. will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir (foscarnet sodium) back from Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.

[Read More]

Clinigen to acquire Link Healthcare

Wednesday, September 23, 2015

Clinigen Group, a specialty global pharmaceutical company, has agreed to acquire Link Healthcare, a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia (AAA) region, for an initial consideration of $67.9 million and a maximum of approximately $152.5 million based on achievement of milestones.

[Read More]

Eisai, Clinigen partner on patient access program in Germany

Monday, September 9, 2013

Eisai EMEA, an R&D based pharmaceutical company, has established a named patient access program to ensure patients continue to receive an uninterrupted supply of the anti-epilepsy drug Fycompa (perampanel), following the temporary suspension of commercial distribution in Germany. The access program will be managed by Clinigen Global Access Programs (GAP), a U.K.-headquartered specialty global pharmaceutical company.

[Read More]